Novo secures Chinese drug rights
7m
Danish drugmaker Novo Nordisk secured global rights to Chinese firm Hengrui Pharma’s experimental weight-loss pill in a deal valued at $2.6 billion.
Reposted by Raffaella Ravinetto
4/4 They, in turn, began selling their products directly to patients, allowing them to reach a broad swath of consumers, including those who may not actually be overweight or obese but want to lose weight.
Read more from @elaineywchen.bsky.social here:
www.statnews.com/2026/09/28/g...
Read more from @elaineywchen.bsky.social here:
www.statnews.com/2026/09/28/g...
Once described as obesity medicines for 'patients,' GLP-1s are increasingly lifestyle drugs for 'customers'
Blockbuster GLP-1 drugs have transformed the lives of millions of people. Lately, they’re undergoing a makeover of their own.
www.statnews.com
September 29, 2026 at 2:03 PM
4/4 They, in turn, began selling their products directly to patients, allowing them to reach a broad swath of consumers, including those who may not actually be overweight or obese but want to lose weight.
Read more from @elaineywchen.bsky.social here:
www.statnews.com/2026/09/28/g...
Read more from @elaineywchen.bsky.social here:
www.statnews.com/2026/09/28/g...